Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia

Thrombosis and Haemostasis

Volumn 85, Issue 2, 2001, Pages 371-372

  Zacharski, L R ^a   Dunbar, S D ^a   Newsom, W A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ACTIVIN RECEPTOR; ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; ANTITHROMBIN III; DESMOPRESSIN; ENDOGLIN; ESTROGEN RECEPTOR; FIBRINOGEN; IRON; PLASMIN INHIBITOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEIN C; PROTEIN S; TAMOXIFEN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA; VON WILLEBRAND FACTOR;

AGED; AUTOSOMAL DOMINANT INHERITANCE; BLOOD TRANSFUSION; BREAST CARCINOMA; CASE REPORT; CAUTERIZATION; DISEASE ASSOCIATION; DRUG MECHANISM; FAMILY HISTORY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOCHEZIA; HEMATOLOGICAL PARAMETERS; HUMAN; IRON THERAPY; LETTER; MASTECTOMY; OCCULT BLOOD; ONSET AGE; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035126564     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615709     Document Type: Letter

References (26)

1. Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement
2. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia
3. The thrombophilic state induced by therapeutic agents in the cancer patient
4. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: A longitudinal study of blood coagulation and fibrinolysis
5. Effect of tamoxifen on von Willebrand factor levels
6. Effect of tamoxifen on measurements of hemostasis in healthy women
7. The influence of tamoxifen in vivo in the main natural anticoagulants and fibrinolysis
8. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer
9. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulation-fibrinolytic systems in patients with advanced breast cancer
10. The influence of tamoxifen on plasma coagulation and serouis fibrinolysis
11. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain
12. Effects of tamoxifen on blood coagulation
13. Hereditary hemorrhagic telangiectasia: Analysis of platelet aggregation and fibrinolytic system in seven patients
14. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden
15. Decision analysis of tamoxifen for the prevention of invasive breast cancer
16. Treatment of cancer with inhibitors of the plasminogen activator - Plasmin system
17. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428
18. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia
19. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia
20. Involvement of the Ras/MAPK signaling pathway in the modulation of urokinase production and cellular invasiveness by transforming growth factor-beta(1) in transformed keratinocytes
21. Sp1 mediates constitutive and transforming growth factor beta-inducible expression of urokinase type plasminogen activator receptor gene in human monocyte-like U937 cells
22. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan
23. Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells
24. Mechanisms of action of the soy isoflavone genestein: Emerging role for its effects via transforming growth factor beta signaling pathways
25. Expression of nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA is inhibited by genistein and wortmannin
26. Clinical application of inhibitors of fibrinolysis